Aureka Biotechnologies
Aureka develops AI-powered digital biology and drug discovery technologies for protein therapeutics. Its platform combines high-throughput synthetic biology, single-cell functional screening, autonomous evolution, and AI-based protein design to generate and evaluate therapeutic candidates. The company also develops an internal pipeline of antibody therapeutics for cardiometabolic and inflammatory diseases.
Funding
Every round, secondary, debt facility or acquisition involving Aureka Biotechnologies that AI Lounge tracks, newest first. Latest: Series B on Aug 10, 2026.
Timeline · 2
In the news
Members see every AI company on AI Lounge with revenue, funding, valuation and investors, searchable and sortable, free.
Create my free account →Log in